No Data
Insider decrases its stake in AnGes(4563.JP) to 29.32%
On Nov 1, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint
Insider decrases its stake in AnGes(4563.JP) to 30.62%
On Oct 31, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint
Volume change rate ranking (9:00) - Bandai Namco, Ine, etc. ranked in.
In the volume change rate ranking, you can understand the market participants' interest in trends such as speculation by comparing the average volume for the past 5 days with the volume on the day of delivery. Top volume change rates [As of 9:32 on October 24] (comparison with the average volume for the past 5 days) Stock code Stock name Volume 5-day average volume Volume change rate Stock price change rate ＜4933＞Ine137400107185.08 154.44% 0.11% ＜1514＞Sumiishi
AnGes---Expansion of genetic investigation target diseases at the company's hygiene inspection office and renewal of the homepage.
On the 22nd, Anges <4563> announced that at their clinical research laboratory, Anges Clinical Research Laboratory, primarily focused on rare genetic disease testing, they expanded the target diseases for genetic testing to include newborn screening diseases (7 diseases). They also announced the renewal of their website. The company currently conducts genetic testing in addition to expanded newborn screening tests, with pediatricians handling subjects who test positive in the screenings.
Insider decrases its stake in AnGes(4563.JP) to 31.91%
On Oct 15, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint
AnGes' genetic treatment product "Collategene" has been designated as a breakthrough therapy.
On the 10th, Anges <4563> announced the effects and prospects of the future development of the pharmaceutical "Colategene", which has been designated for breakthrough therapy. "Colategene" is a gene therapy product developed by the company in the usa, and has been designated as a breakthrough therapy by the Food and Drug Administration (FDA) in the usa. Breakthrough therapy aims to expedite the development and evaluation of drugs for the treatment of serious symptoms by the FDA.
No Data
No Data